115 related articles for article (PubMed ID: 2028443)
21. Structure-activity relationships of heparin. Independence of heparin charge density and antithrombin-binding domains in thrombin inhibition by antithrombin and heparin cofactor II.
Hurst RE; Poon MC; Griffith MJ
J Clin Invest; 1983 Sep; 72(3):1042-5. PubMed ID: 6688430
[TBL] [Abstract][Full Text] [Related]
22. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
[TBL] [Abstract][Full Text] [Related]
23. Laboratory determination of heparin cofactor II.
Ezenagu LC; Brandt JT
Arch Pathol Lab Med; 1986 Dec; 110(12):1149-51. PubMed ID: 3778142
[TBL] [Abstract][Full Text] [Related]
24. Laboratory diagnosis of antithrombin and heparin cofactor II deficiency.
Tollefsen DM
Semin Thromb Hemost; 1990 Apr; 16(2):162-8. PubMed ID: 2191430
[TBL] [Abstract][Full Text] [Related]
25. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides.
Sie P; Ofosu F; Fernandez F; Buchanan MR; Petitou M; Boneu B
Br J Haematol; 1986 Dec; 64(4):707-14. PubMed ID: 2432917
[TBL] [Abstract][Full Text] [Related]
26. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
Scully MF; Ellis V; Seno N; Kakkar VV
Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
[TBL] [Abstract][Full Text] [Related]
27. Thrombin inhibitory activity of heparin cofactor II depends on the molecular weight and sulfate amount of dextran sulfate.
Yamagishi R; Niwa M; Sakuragawa N
Thromb Res; 1986 Nov; 44(3):347-54. PubMed ID: 2432675
[TBL] [Abstract][Full Text] [Related]
28. [The antithrombin action of stichopus japonicus acid mucopolysaccharide (Sjamp) is mediated by heparin cofactor II].
Zhang G
Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):126-9. PubMed ID: 15622771
[TBL] [Abstract][Full Text] [Related]
29. The inhibition of thrombin and chymotrypsin by heparin-cofactor II.
Struss D; Storck J; Zimmermann RE
Thromb Res; 1992 Oct; 68(1):45-56. PubMed ID: 1333106
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
Buchanan MR; Brister SJ
Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
32. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
[TBL] [Abstract][Full Text] [Related]
33. Antithrombin activity of a fucan sulfate from the brown seaweed Ecklonia kurome.
Nishino T; Aizu Y; Nagumo T
Thromb Res; 1991 Jun; 62(6):765-73. PubMed ID: 1926066
[TBL] [Abstract][Full Text] [Related]
34. Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Kario K; Matsuo T; Kodama K; Katayama S; Kobayashi H
Thromb Res; 1992 May; 66(4):435-44. PubMed ID: 1412208
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Lopaciuk S; Bykowska K; Kopeć M
Pol J Pharmacol; 1996; 48(1):109-11. PubMed ID: 9112638
[TBL] [Abstract][Full Text] [Related]
36. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
[TBL] [Abstract][Full Text] [Related]
37. Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II.
Sié P; Petitou M; Lormeau JC; Dupouy D; Boneu B; Choay J
Biochim Biophys Acta; 1988 Aug; 966(2):188-95. PubMed ID: 3401503
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate.
Sié P; Fernandez F; Caranobe C; Gabaig AM; Boneu B
Thromb Res; 1984 Jul; 35(2):231-6. PubMed ID: 6206589
[No Abstract] [Full Text] [Related]
39. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
40. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
Shimotori T; Sakuragawa N
Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
